SHANGHAI, Feb. 11, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic...
Hence then, the article about novel anti fibrotic drug ak3280 cleared by fda to initiate phase 2 proof of concept clinical trial in ipf was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF )
Also on site :
- Police: Two killed in shooting at West San Jose shopping center
- Judge Rules That ICE Agents Violate the Fourth Amendment by Making Arrests While Masked
- Google’s new 1.9GW clean energy deal includes massive 100-hour battery